Exercise throughout chemotherapy reduces cognitive impairment, inflammation
the ONA take:
According to a study presented at the 2015 American Society of Clinical Oncology annual meeting this week, researchers from the University of Rochester have found that patients with cancer who exercise throughout chemotherapy had reduced chronic inflammation and cognitive impairment.
For the phase III study, researchers enrolled 619 patients with early-stage cancer. Participants were randomly assigned to receive standard care (no prescribed exercise during chemotherapy) or a specialized program labelled EXCAP. Patients in the EXCAP group walked daily and used resistance bands as instructed while also wearing a pedometer to track steps walked.
Results showed that patients in the standard care group experienced reduced mobility and increased brain fogginess and memory problems. Those patients also had higher levels of blood inflammation. Subgroup analyses showed patients who received chemotherapy in 2-week cycles experienced the most benefit from EXCAP.
"To think that a very simple, low-cost, self-directed exercise prescription can create an anti-inflammatory response similar to a drug and protect against cognitive decline in people with cancer is innovative and very exciting," said Karen M. Mustian, PhD, MPH, associate professor in the University of Rochester Departments of Surgery and Radiation Oncology.
Patients with cancer who exercise throughout chemotherapy had reduced chronic inflammation and cognitive impairment.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|